Citadel Advisors
CLGN icon

Citadel Advisors’s CollPlant Biotechnologies CLGN Stock Holding History

Citadel Advisors’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$2.69K – 14363
2024
Q1 		$2.69K Sell
500
-1,200
-71% -$6.49K ﹤0.01% 13980
2023
Q4 		$10.9K Buy
+1,700
New +$9.3K ﹤0.01% 13079

Other funds holding CLGN

SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $201M AUM 259.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors's CLGN Position: Q1 2026 in Review

Citadel Advisors opened a new position in CollPlant Biotechnologies (CLGN) in Q1 2026: 32,165 shares worth $17.2K. The stake represents ﹤0.01% of the portfolio and ranks #12700 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CLGN as recently as Q1 2024.

Citadel Advisors first reported a position in CLGN in Q3 2018 and has held it in 8 quarters since. The position peaked at $276K in Q2 2021. 21 funds tracked by Wall St. Rank hold CLGN as of Q1 2026.

  • Citadel Advisors held 32,165 shares of CollPlant Biotechnologies worth $17.2K as of Q1 2026.
  • CollPlant Biotechnologies was a new Citadel Advisors position in Q1 2026.
  • CollPlant Biotechnologies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12700 holding.
  • Citadel Advisors first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 8 quarters since.
  • Citadel Advisors's CollPlant Biotechnologies position peaked at $276K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.